Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients

2019 ◽  
Vol 38 (4) ◽  
pp. S119-S120 ◽  
Author(s):  
C.S. King ◽  
S.S. Aryal ◽  
A. Cochrane ◽  
A. Brown ◽  
O. Shlobin ◽  
...  
2019 ◽  
Vol 21 (6) ◽  
Author(s):  
Shambhu Aryal ◽  
Shalika B. Katugaha ◽  
Adam Cochrane ◽  
Anne Whitney Brown ◽  
Steven D. Nathan ◽  
...  

1998 ◽  
Vol 65 (Supplement) ◽  
pp. 215
Author(s):  
T M Hoffman ◽  
T L Spray ◽  
J W Gaynor ◽  
B J Clark ◽  
N D Bridges

1998 ◽  
Vol 65 (12) ◽  
pp. S139
Author(s):  
T M Hoffman ◽  
T L Spray ◽  
J W Gaynor ◽  
B J Clark ◽  
N D Bridges

2000 ◽  
Vol 4 (2) ◽  
pp. 112-117 ◽  
Author(s):  
Timothy M. Hoffman ◽  
Thomas L. Spray ◽  
James W. Gaynor ◽  
Bernard J. Clark ◽  
Nancy D. Bridges

2013 ◽  
Vol 57 (8) ◽  
pp. 4058-4060 ◽  
Author(s):  
J. Trevillyan ◽  
P. Angus ◽  
E. Shelton ◽  
J. Whitlam ◽  
F. Ierino ◽  
...  

ABSTRACTIn a prospective study of solid-organ transplant recipients (n= 22; 15 hepatic and 7 renal) receiving valganciclovir for cytomegalovirus (CMV) prophylaxis, electronic estimation of glomerular filtration rate (eGFR) underestimated the true GFR (24-h urine creatinine clearance) by >20% in 14/22 (63.6%). Its use was associated with inappropriate underdosing of valganciclovir, while the Cockroft-Gault equation was accurate in 21/22 patients (95.4%). Subtherapeutic ganciclovir levels (≤0.6 mg/liter) were common, occurring in 10/22 patients (45.4%); 7 had severely deficient levels (<0.3 mg/liter).


2000 ◽  
Vol 69 (Supplement) ◽  
pp. S238
Author(s):  
Paolo A. Grossi ◽  
Daniela Dalla Gasperina ◽  
Milena Furione ◽  
Enrico Silini ◽  
Carlo Campana ◽  
...  

1999 ◽  
Vol 13 (1-2) ◽  
pp. 37-42 ◽  
Author(s):  
A. Calvet ◽  
M.O. Pujol ◽  
M. Bertocchi ◽  
O. Bastien ◽  
P. Boissonnat ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document